Screener
Spyre Therapeutics, Inc. SYRE Total Revenue
Discontinued — last reported Q4 '25
Total Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026.
- Filed
- Feb 19, 2026, 4:01 PM EST
- Fiscal year
- FY2025
- Accession
- 0001636282-26-000020
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Revenue: | |||
| Development fee and royalty | — | — | 886 |
| Total revenue | — | — | 886 |
| Operating expenses: | |||
| Research and development (1) | 171,653 | 162,790 | 89,504 |
| General and administrative (2) | 47,909 | 45,776 | 39,946 |
| Acquired in-process research and development | — | — | 130,188 |
| Gain on sale of in-process research and development asset | (10,000) | — | (16,449) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Spyre Therapeutics, Inc.'s total revenue?
- Spyre Therapeutics, Inc. (SYRE) reported total revenue of $0 in Q4 2025.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $18.74M to $0.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Spyre Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude